114 related articles for article (PubMed ID: 34895063)
21. Application of Lung-Targeted Lipid Nanoparticle-delivered mRNA of soluble PD-L1 via SORT Technology in Acute Respiratory Distress Syndrome.
Sun H; Zhang Y; Wang J; Su J; Zhou D; Yu X; Xu Y; Yang W
Theranostics; 2023; 13(14):4974-4992. PubMed ID: 37771784
[No Abstract] [Full Text] [Related]
22. Ionizable Lipid Nanoparticle-Mediated TRAIL mRNA Delivery in the Tumor Microenvironment to Inhibit Colon Cancer Progression.
da Silva WN; Carvalho Costa PA; Scalzo Júnior SRA; Ferreira HAS; Prazeres PHDM; Campos CLV; Rodrigues Alves MT; Alves da Silva NJ; de Castro Santos AL; Guimarães LC; Chen Ferris ME; Thatte A; Hamilton A; Bicalho KA; Lobo AO; Santiago HDC; da Silva Barcelos L; Figueiredo MM; Teixeira MM; Vasconcelos Costa V; Mitchell MJ; Frézard F; Pires Goulart Guimaraes P
Int J Nanomedicine; 2024; 19():2655-2673. PubMed ID: 38500680
[TBL] [Abstract][Full Text] [Related]
23. Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering.
Hamilton AG; Swingle KL; Joseph RA; Mai D; Gong N; Billingsley MM; Alameh MG; Weissman D; Sheppard NC; June CH; Mitchell MJ
Adv Healthc Mater; 2023 Dec; 12(30):e2301515. PubMed ID: 37602495
[TBL] [Abstract][Full Text] [Related]
24. Towards the Application of a Label-Free Approach for Anti-CD47/PD-L1 Bispecific Antibody Discovery.
Grevtsev AS; Azarian AD; Misorin AK; Chernyshova DO; Iakovlev PA; Karbyshev MS
Biosensors (Basel); 2023 Dec; 13(12):. PubMed ID: 38131782
[TBL] [Abstract][Full Text] [Related]
25. Anti-PD-1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2-Positive Gastric Cancer through Gasdermin B-Cleavage Induced Pyroptosis.
Lin W; Zhang Y; Yang Y; Lin B; Zhu M; Xu J; Chen Y; Wu W; Chen B; Chen X; Liu J; Wang H; Teng F; Yu X; Wang H; Lu J; Zhou Q; Teng L
Adv Sci (Weinh); 2023 Oct; 10(30):e2303908. PubMed ID: 37587833
[TBL] [Abstract][Full Text] [Related]
26. Development and validation of ELISA method for quantification of Q-1802 in serum and its application to pharmacokinetic study in ICR Mouse.
Meng Q; Hao Y; Yang M; Du Y; Wang S
J Pharm Biomed Anal; 2024 Aug; 245():116138. PubMed ID: 38636191
[TBL] [Abstract][Full Text] [Related]
27. Effective delivery of anti-PD-L1 siRNA with human heavy chain ferritin (HFn) in acute myeloid leukemia cell lines.
Rajabinejad M; Valadan R; Tehrani M; Najafi A; Negarandeh R; Saeedi M; Asgarian-Omran H
Med Oncol; 2024 May; 41(6):149. PubMed ID: 38739199
[TBL] [Abstract][Full Text] [Related]
28. IL7 increases targeted lipid nanoparticle-mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation.
Tilsed CM; Sadiq BA; Papp TE; Areesawangkit P; Kimura K; Noguera-Ortega E; Scholler J; Cerda N; Aghajanian H; Bot A; Mui B; Tam Y; Weissman D; June CH; Albelda SM; Parhiz H
Proc Natl Acad Sci U S A; 2024 Mar; 121(13):e2319856121. PubMed ID: 38513098
[TBL] [Abstract][Full Text] [Related]
29. Interferon Biology and LAG-3 Shedding in PD-(L)1 plus LAG-3 Immunotherapy.
Karapetyan L; Luke JJ
Clin Cancer Res; 2023 Mar; 29(5):835-837. PubMed ID: 36534010
[TBL] [Abstract][Full Text] [Related]
30. Delivery of mRNA Encoding Interleukin-12 and a Stimulator of Interferon Genes Agonist Potentiates Antitumor Efficacy through Reversing T Cell Exhaustion.
Wang B; Tang M; Chen Q; Ho W; Teng Y; Xiong X; Jia Z; Li X; Xu X; Zhang XQ
ACS Nano; 2024 Jun; 18(24):15499-15516. PubMed ID: 38832815
[TBL] [Abstract][Full Text] [Related]
31. Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy.
Zong Y; Lin Y; Wei T; Cheng Q
Adv Mater; 2023 Dec; 35(51):e2303261. PubMed ID: 37196221
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4.
Zeng J; Fang Y; Zhang Z; Lv Z; Wang X; Huang Q; Tian Z; Li J; Xu W; Zhu W; Yu J; Liu T; Qian Q
Oncogene; 2024 May; ():. PubMed ID: 38806619
[TBL] [Abstract][Full Text] [Related]
33. Development of anti-PD-L1 antibody based on structure prediction of AlphaFold2.
Du K; Huang H
Front Immunol; 2023; 14():1275999. PubMed ID: 37942332
[TBL] [Abstract][Full Text] [Related]
34. mRNA lipid nanoparticle-mediated pyroptosis sensitizes immunologically cold tumors to checkpoint immunotherapy.
Li F; Zhang XQ; Ho W; Tang M; Li Z; Bu L; Xu X
Nat Commun; 2023 Jul; 14(1):4223. PubMed ID: 37454146
[TBL] [Abstract][Full Text] [Related]
35. Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer.
Miller KM; Friedman CF
Clin Cancer Res; 2022 Dec; 28(24):5238-5240. PubMed ID: 35947045
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy.
Zhao Y; Gan L; Ke D; Chen Q; Fu Y
J Transl Med; 2023 Oct; 21(1):693. PubMed ID: 37794448
[TBL] [Abstract][Full Text] [Related]
37. Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy.
Han J; Lim J; Wang CJ; Han JH; Shin HE; Kim SN; Jeong D; Lee SH; Chun BH; Park CG; Park W
Nano Converg; 2023 Aug; 10(1):36. PubMed ID: 37550567
[TBL] [Abstract][Full Text] [Related]
38. Enhanced Local Delivery of Engineered IL-2 mRNA by Porous Silica Nanoparticles to Promote Effective Antitumor Immunity.
Shin H; Kang S; Won C; Min DH
ACS Nano; 2023 Sep; 17(17):17554-17567. PubMed ID: 37643221
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo.
Kauffman KJ; Mir FF; Jhunjhunwala S; Kaczmarek JC; Hurtado JE; Yang JH; Webber MJ; Kowalski PS; Heartlein MW; DeRosa F; Anderson DG
Biomaterials; 2016 Dec; 109():78-87. PubMed ID: 27680591
[TBL] [Abstract][Full Text] [Related]
40. Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody.
Bähr-Mahmud H; Ellinghaus U; Stadler CR; Fischer L; Lindemann C; Chaturvedi A; Diekmann J; Wöll S; Biermann I; Hebich B; Scharf C; Siefke M; Roth AS; Rao M; Brettschneider K; Ewen EM; Şahin U; Türeci Ö
Oncoimmunology; 2023; 12(1):2255041. PubMed ID: 37860278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
